权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Usefulness of continuous porous hydroxyapatite ceramics with bone marrow stromal cells

连续多孔羟基磷灰石陶瓷与骨髓基质细胞的用途

基本信息

批准号：
14370672
负责人：
UEYAMA Yoshiya
金额：
$ 8.58万
依托单位：
Yamaguchi University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2002
资助国家：
日本
起止时间：
2002 至 2004
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14370672/
关键词：
continuous porous hydroxyapataite ceramic bone marrow stromal cell bone regeneration

项目摘要

1.The continuous porous hydroxyapatite ceramics (cp-HA) consisted of β-tricalcium phosphate (β-TCP) known as bone displacement materials, and α-tricalcium phosphate (α-TCP) as a thermophile stable phase, and it's characteristics is that the porosity was about 85mm, and the pore diameter was about 0.8mm. Furthermore, we tried making of a cp-HA which lowered pore diameter by the range that osteoblast could infiltrate as much as possible to add to intensity, but pore was clogged up by surface tension of suspension to dip a soft firing polyurethane form to 10% silicon dioxide component apatite suspension by manufacture methods of the cp-HA which we used by this study, and the manufacture of lower than porous diameter 0.8mm cp-HA was impossible. Therefore the experiment was used cp-HA of pore diameter 1.0mm and 0.8mm.2.In a difference (1.0mm and 0.8mm) of the pore diameter used for the experiment, the difference was not found in ossiferous quantity and bone formation rate. It is thought that this is not different in an invasion of osteoblast to pores in a difference of porous diameter of this level. But a cp-HA whose pore diameter is massive becomes fragile, then it is not used for clinic. In addition, we confirmed that cpHA contacted new bone directly without connective tissue in pore, but cp-HA did not resorb in vivo and was not replaced by bone.3.In order to make cp-HA included BMSC, it was necessary to mix fibrinogen with BMSC. The difference of quantity of new bone was not confirmed in a condition of cp-HA included BMSC and cp-HA only in 6 months and 12 months, namely a middle long term, in vivo. However, it is though that the experiment in a short term will need in future because the effect of a BMSC component may appear earlier.

1.连续多孔羟基磷灰石陶瓷（cp-HA）是由β-磷酸三钙（β-TCP）和α-磷酸三钙（α-TCP）组成的多孔陶瓷，其特点是孔隙率约为85 mm，孔径约为0.8mm。此外，我们尝试制造cp-HA，其将孔径降低成骨细胞可以尽可能多地渗透的范围以增加强度，但是孔被悬浮液的表面张力堵塞，以通过我们在本研究中使用的cp-HA的制造方法将软烧聚氨酯形式浸入10%二氧化硅组分磷灰石悬浮液中，而孔径小于0.8mm的cp-HA的制备是不可能的。2.在实验所用的不同孔径（1.0mm和0.8mm）中，成骨量和成骨率没有发现差异。据认为，这在成骨细胞对该水平的不同孔径的孔的侵入中没有不同。但由于孔径较大的cp-HA变得易碎，因此不能用于临床。此外，我们还证实了cp-HA与新骨直接接触，孔隙内无结缔组织，而cp-HA在体内不吸收，不被骨所取代。3.为了使cp-HA包含BMSC，需要将纤维蛋白原与BMSC混合。仅在体内6个月和12个月（即中长期），在包含BMSC和cp-HA的cp-HA条件下，新骨数量的差异尚未得到证实。但是，由于BMSC组分的作用可能会更早出现，因此短期内的实验将需要在未来进行。